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ABSTRACT 
Background: Fractalkine (FKN) induces activation and adhesion of leukocytes 
expressing its receptor, CX3CR1.  FKN is released from the cell surface by proteolytic 
cleavage as soluble FKN (sFKN). 






3CR1 expression on blood leukocytes in atopic dermatitis (AD) patients. 
Methods: FKN and CX3CR1 expression in the skin was examined 
immunohistochemically.  mRNA expression of FKN, thymus and activation regulated 
chemokine (TARC), and macrophage derived chemokine (MDC) in the skin was 
assessed by real-time RT-PCR.  Serum sFKN levels were assessed by ELISA.  Blood 
leukocytes were stained for CX3CR1 with flow cytometric analysis.   
Results: FKN was strongly expressed on endothelial cells in skin lesions of AD and 
psoriasis, but not in normal skin.  FKN mRNA levels in AD lesional skin increased to 
a similar extent to TARC and MDC mRNA levels.  CX3CR1-expressing cells in the 
affected skin of patients with AD or psoriasis increased compared with normal skin.  
Serum sFKN levels were elevated in AD patients but not in psoriasis patients relative to 
normal controls.  Serum sFKN levels were associated with the disease severity, and 
decreased with the improvement of skin lesion in AD patients.  The frequency of 
CX3CR1+ cells and CX3CR1 expression levels were decreased in CD8+ T cells, 
monocytes, and NK cells from AD patients, which were not observed in psoriasis 
patients.   
Conclusions: These results suggest that, through functions in both membrane-bound 
and soluble forms, FKN plays important roles in trafficking of CX3CR1+ leukocytes 
during the inflammation of AD. 
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sFKN: soluble fractalkine 
AD: Atopic dermatitis 
Th: T helper 5 
10 
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IFN: interferon  
IL: interleukin 
NK: natural killer 
Ab: antibody 
TARC: Thymus and activation regulated chemokine 
MDC: Macrophage derived chemokine 
mAb: monoclonal antibody 
CLA: cutaneous lymphocyte antigen 
RT-PCR: reverse transcription-polymerase chain reaction 
GAPDH: Glyceraldehyde-3-phosphate 
TACE: tumor necrosis factor-α-converting enzyme 
TIMP: tissue inhibitors of metalloproteinase 
CTL: normal controls 
Contact D: contact dermatitis  
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INTRODUCTION 
    Atopic dermatitis (AD) is a chronic, highly pruritic, inflammatory skin disease 
that manifests as eczematous skin lesions 1-3.  A skin lesion in AD is characterized by 
preferential infiltration of activated T cells, monocytes/macrophages, and eosinophils.  
Although it has been proposed that T helper (Th) 2-type cells play a key role in the 






4-8, recent studies have revealed that Th1-type cytokines, including 
interferon (IFN)-γ and interleukin (IL)-12, are predominantly expressed in chronic 
lesions of AD 6,9,10.  Furthermore, chronic activation of macrophages/monocytes with 
increased cytokine secretion is the other immune dysfunction that characterizes AD 11.  
The development of cutaneous lesions in AD is closely related to the accumulation of 
these leukocytes migrating from the blood into the affected skin through the 
endothelium.  This process is highly dependent on expression of chemokines and 
chemokine receptors as well as adhesion molecules 7.  
Fractalkine (FKN) or CX3CL1 is a CX3C chemokine that is expressed on 
activated vascular endothelial cells stimulated with IL-1, tumor necrosis factor-α, or 
IFN-γ12,13.  FKN is expressed in various organs including skin, tonsils, brain, and 
kidney 12,14-16 and interacts with its unique receptor, CX3CR1, expressed on monocytes, 
natural killer (NK) cells, and some T cells.  FKN and CX3CR1 represent a novel type 
of leukocyte trafficking molecule that regulates both adhesive and chemotactic 
functions 17.  The membrane-bound FKN is able to mediate firm adhesion of 
CX3CR1-expressing leukocytes without requiring selectin-mediated rolling or activation 
of integrins 18,19.  Furthermore, FKN is released from the cell surface by proteolytic 
cleavage as soluble FKN (sFKN) that has potent chemoattractant activity for CX3CR1+ 
leukocytes and activates them 12,17,20.  Since CX3CR1 is preferentially expressed on Th1 
cells compared to Th2 cells, cell infiltration via FKN-CX3CR1 interaction especially 
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promotes Th1 responses 13.  Recent studies have demonstrated that FKN-CX3CR1 
interaction contributes to the development of various inflammatory diseases and 
vascular injury by recruiting inflammatory cells 19.  
These previous findings suggest the involvement of FKN-CX3CR1 interaction 
in the induction and development of inflammatory processes associated with AD.  
Therefore, we evaluated expression of FKN and CX
5 
10 
3CR1 in the skin, serum sFKN 
levels, and CX3CR1 expression on circulating leukocytes in AD.  The results of this 
study suggest that, through functions in both membrane-bound and soluble forms, FKN 
plays important roles in the trafficking of CX3CR1+ leukocytes during the inflammation 
of AD. 
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METHODS 
Patients and control subjects for sFKN measurement  
Serum sFKN levels were examined in 32 patients with AD (13 females and 19 
males, 24.7 ± 7.4 years old).  All patients fulfilled the criteria for AD proposed by 
Hannifin and Rajka 1 and they did not have any history of other atopic diseases such as 
bronchial asthma and allergic rhinitis.  The clinical severity of AD was evaluated using 






21: 16 patients had moderate-type 
AD and 16 patients had severe-type AD.  The clinical data and serum samples were 
obtained at the same time.  All patients were treated with topical steroids in 
combination with oral anti-allergic drugs.  However, none of the patients were treated 
with systemic steroids or immunosuppressive drugs.  In addition, patients with contact 
dermatitis (n=15, 8 females and 7 males, 24.3 ± 2.5 years old) or psoriasis vulgaris 
(n=23, 10 females and 13 males, 30.5 ± 5.9 years old), both of which are considered 
Th1-mediated skin diseases, were examined as disease controls in this study.  The 
control subjects were sex- and age-matched 30 healthy Japanese individuals (12 females 
and 18 males, 26.7 ± 4.5 years old).  To assess the effect of treatment on serum sFKN 
levels, we examined sFKN levels before and after treatment in 23 patients with 
severe-type AD (8 females and 15 males, 22.8 ± 7.2 years old).  These patients were 
intensively treated with topical steroids in combination with oral anti-allergic drugs 
during 2 weeks of hospitalization.  None of these patients were treated with systemic 
steroids or immunosuppressive drugs.  Serum specimens were aliquoted and kept 
frozen at -70°C before use.  The protocol was approved by the Committee at 
Kanazawa University Graduate School of Medical Science and informed consent was 
obtained from all patients and normal individuals. 
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ELISA for sFKN 
Unless indicated otherwise, reagents were obtained from R&D Systems 
(Minneapolis, MN).  Human sFKN levels were measured in serum samples by specific 
ELISA.  Briefly, 96-well polystyrene plates were coated overnight at 25oC with 2 
μg/ml of purified goat IgG anti-human FKN antibody (Ab).  After washing, plates 
were blocked for 1 hour at 20oC with a phosphate-buffered saline containing 1% bovine 
serum albumin and 5% sucrose.  Recombinant human FKN and serum samples were 
added in triplicate and the plates were incubated for 2 hours at 20oC.  After washing, 
the plates were incubated with biotinylated goat anti-human FKN Ab (250 ng/ml) for 2 
hours at 20oC and then with streptavidin-peroxidase for 1 hour at 20oC.  Samples were 
developed with 0.1 ml/well of tetramethylbenzidine substrate diluted in a 






2SO4 and the plates 
were read at 450 nm.  Thymus and activation regulated chemokine (TARC/CCL17) 
and Macrophage derived chemokine (MDC/CCL22), which are known as Th2-type 
chemokines 22, were also examined by ELISA. 
 
Flow cytometric analysis 
CX3CR1 expression levels by peripheral blood leukocytes were examined in 
patients with AD (n=16, 10 severe and 6 moderate AD patients, 7 females and 9 males, 
25.5 ± 5.8 years old), those with psoriasis (n=8, 4 females and 4 males, 33.2 ± 7.8 years 
old), and normal controls (n=10, 4 females and 6 males, 28.3 ± 6.2 years old).  
Heparinized blood samples were collected and immediately placed on ice.  Two-color 
analysis was performed with a combination of FITC-conjugated anti-CX3CR1 
monoclonal Ab (mAb; Medical & Biological laboratories Corp., Nagoya, Japan) and 
phycoerythrin-conjugated anti-CD4 (Coulter Corp., Miami, FL), anti-CD8 (Coulter 
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Corp.), anti-CD14 (Coulter Corp.), or anti-CD16 (Coulter Corp.) mAbs.  Three-color 
analysis was also conducted with a combination of FITC-conjugated anti-CX3CR1 
(Medical & Biological laboratories Corp.), biotinylated anti-cutaneous lymphocyte 
antigen (CLA; BD PharMingen, San Diego, CA), and peridinin chlorophyll 
protein-conjugated anti-CD4 (BD PharMingen) mAbs.  Phycoerythrin conjugated 
streptavidin (Southern Biotechnology Associates Inc, Birmingham, Ala) was used for 
reveal biotin-coupled Ab staining.  The blood samples were stained at 4oC with a 







23.  Blood erythrocytes were lysed with the Coulter Whole Blood 
Immuno-Lyse kit as instructed by the manufacturer (Coulter Corp.).  Cells were 
washed and analyzed with a FACScan flow cytometer (BD PharMingen).  The positive 
and negative population of cells was determined with the unreactive isotype-matched 
mAbs (Coulter Corp.) as a control for background staining.  
 
Immunohistochemical staining 
FKN and CX3CR1 expression in the skin was determined by the 
immunohistochemical staining in AD patients with chronic skin lesions (n=9, 4 females 
and 5 males, 28.0 ± 5.5 years old), patients with psoriasis (n=5, 2 females and 3 males, 
34.1 ± 7.2 years old), and normal controls (n=4, 2 females and 2 males, 29.6 ± 4.8 years 
old), as previously described 24.  Briefly, formalin-fixed paraffin-embedded skin tissues 
were acetone-fixed and then incubated with 10% normal rat serum for 10 minutes at 
37oC to block non-specific staining.  Sections were stained with goat polyclonal IgG 
Ab specific for human FKN (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or rabbit 
polyclonal IgG Ab specific for human CX3CR1 (Chemicon International, Temecula, 
CA).  Sections were incubated sequentially (20 minutes, 37oC) with biotinylated rabbit 
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anti-goat IgG secondary Ab for FKN staining or with biotinylated goat anti-rabbit IgG 
secondary Ab for CX3CR1 staining (Vectastatin avidin-biotin complex methods, Vector 
Laboratories, Burlingame, CA), then with horseradish peroxidase-conjugated 
avidin-biotin complexes (Vector Laboratories).  Sections were finally developed with 
3,3’-diaminobenzidine tetrahydrochloride and hydrogen peroxide, and counter-stained 
with methyl green.  In a similar way, the serial skin tissues were stained with anti-CD3, 
anti-CD4, anti-CD8, anti-CD14, anti-CD16, anti-CD20, and anti-CD68 Abs 






3CR1-expressing cells.  
 
RNA isolation and real-time reverse transcription (RT)-polymerase chain reaction 
(PCR) 
Total RNA was isolated from frozen tissue of 5 chronic skin lesions of AD 
patients (3 females and 2 males, 27.4 ± 4.6 years old), and 5 normal controls (3 females 
and 2 males, 28.2 ± 4.2 years old) with QIAGEN RNeasy spin columns (QIAGEN Ltd., 
Crawley, UK).  Total RNA from each sample was reversely transcribed into cDNA.  
Expression of FKN, TARC, and MDC was analyzed using a real-time PCR 
quantification method according to the manufacture’s instructions (Applied Biosystems, 
Foster City, CA).  Sequence-specific primers and probes were designed by 
Pre-Developed TaqMan® Assay Reagents or Assays-On-DemandsTM (Applied 
Biosystems).  Real-time PCR (40 cycles of denaturation at 92°C for 15 seconds, 
annealing at 60°C for 60 seconds) was performed on an ABI Prism 7000 Sequence 
Detector (Applied Biosystems).  Glyceraldehyde-3-phosphate (GAPDH) was used to 
normalize mRNA.  To compare target gene and housekeeping (GAPDH) gene mRNA 
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expression, relative expression of real-time PCR products was determined using the 
ΔΔCt method 25.  One of the control samples was chosen as a calibrator sample.   
 
Statistical Analysis 
 The Mann-Whitney U tests were used to compare variables between 2 groups 
and Bonferroni’s test was used for multiple comparisons.  Spearman's rank correlation 
coefficient was used to examine the relationship between two continuous variables.  A 
p value <0.05 was considered statistically significant.  All data are shown as mean ± 
SD.  
5 
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RESULTS  
Expression of FKN and CX3CR1 in the skin  
We performed immunohistochemical analysis using specific Ab to assess 
FKN expression in the affected skin from patients with AD.  In the skin from normal 
individuals, FKN was not expressed on endothelial cells.  In contrast, vascular 
endothelial cells strongly expressed FKN in the affected skin, but not in the unaffected 
skin of patients with AD or psoriasis (Fig. 1A and data not shown).  Then, we 






3CR1+ cells in the skin lesions from AD patients (Fig. 
1B).  CX3CR1+ cells were sparsely detected by immunohistochemical staining in 
normal control skin tissues (1 ± 3% of infiltrating mononuclear cells).  In contrast, a 
considerable rate of infiltrating cells expressed CX3CR1 in the affected skin tissues 
from AD patients (27 ± 19%) and psoriasis patients (23 ± 17%).  Most of CX3CR1+ 
cells were identified as CD3+ T cells in AD patients (80 ± 32%) and psoriasis patients 
(78 ± 23%).  The expression ratio of CD4/CD8 in infiltrating CD3+ CX3CR1+ cells 
was similar in AD patients (1.2 ± 0.6) and psoriasis patients (1.3 ± 0.6).  Thus, the 
endothelial FKN expression was augmented with increased infiltration of CX3CR1+ 
cells in the lesional skin from AD as well as psoriasis. 
 
Expression of FKN, TARC, and MDC mRNA in the skin 
To determine the relative importance of FKN in comparison of TARC and 
MDC, Th2-type chemokines that have been shown to be involved in the AD skin 
inflammation 26, we examined mRNA expression of FKN, TARC, and MDC in the AD 
lesional skin by real-time RT-PCR.  FKN mRNA levels in AD patients were 
significantly 8.7-fold higher than those in normal controls (14.8 ± 12.2 vs. 1.7 ± 1.5, 
p<0.05).  Similarly, TARC mRNA levels in AD patients were significantly 7.6-fold 
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higher than those in normal controls (24.7 ± 14.5 vs. 3.2 ± 2.0, p<0.05) while MDC 
mRNA levels in AD patients were significantly increased by 7.9-fold compared with 
normal controls (13.4 ± 9.0 vs. 1.7 ± 1.4, p<0.05).  Thus, mRNA expression levels of 





Serum sFKN levels 
 Since FKN is released from the cell surface as a soluble form 12, sFKN levels 
were assessed in serum samples from AD patients (Fig. 2).  Serum sFKN levels in 
patients with AD were significantly 5.1-fold higher than those in normal controls (81 ± 
153 vs. 16 ± 11 pg/ml, p<0.05).  By contrast, patients with psoriasis (34 ± 51 pg/ml) or 
contact dermatitis (22 ± 20 pg/ml) showed mean sFKN levels similar to those of normal 
controls.  The affected skin area was similar in AD patients (52 ± 23% of total body) 
and psoriasis patients (49 ± 26%), suggesting that sFKN levels were not simply 
determined by the extent of skin disease.  Regarding the severity of AD, severe AD 
patients (141 ± 201 pg/ml) exhibited significantly increased sFKN levels compared with 
moderate AD patients (21 ± 15 pg/ml, p<0.05).  Furthermore, sFKN levels were 
significantly elevated in severe AD patients relative to patients with psoriasis (p<0.05) 
or contact dermatitis (p<0.05) as well as normal controls (p<0.005).  However, sFKN 
levels in moderate AD patients were comparable with those in normal controls.  Blood 
eosinophil numbers and serum IgE levels did not correlate with the serum sFKN levels 
in AD patients (data not shown).  We determined correlation of sFKN levels with 
serum levels of TARC and MDC that are increased in sera form AD patients 27,28. Serum 
sFKN levels correlated positively with serum levels of TARC (r=0.757, p<0.0001) or 
MDC (r=0.370, p<0.05).  Thus, serum sFKN levels were elevated in patients with AD, 
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especially severe AD, but not in other skin disorders, including psoriasis and contact 
dermatitis.   
To determine the treatment effect on sFKN levels, 23 patients with severe AD 
were examined for serum sFKN levels before and after treatment.  The skin lesions in 
all patients significantly improved (the score changed from 7.6 ± 1.2 to 4.7 ± 1.3, 
p<0.0001) by intensive therapy of topical steroids and oral anti-allergic drugs during 2 
weeks of hospitalization.  Similarly, serum sFKN levels in AD patients were 
significantly decreased by 31% after treatment compared with those before treatment 
(100 ± 191 vs. 69 ± 118 pg/ml, p<0.05).  Thus, serum sFKN levels correlated with the 







Frequency of CX3CR1-expressing cells in blood leukocytes and CX3CR1 
expression levels on blood leukocytes 
 CX3CR1 expression on peripheral blood CD8+ T cells, CD4+ T cells, CD14+ 
monocytes, and CD16+ NK cells was assessed by flow cytometry with two-color 
analysis (Figs. 3 and 4).  The frequency of CD8+ T cells, CD4+ T cells, monocytes, and 
NK cells was not significantly different among AD patients, psoriasis patients, and 
normal controls (data not shown).  The frequency of CX3CR1-expressing cells in 
CD8+ T cells was significantly decreased in AD patients compared with normal controls 
(p<0.05) and psoriasis patients (p<0.05).  CX3CR1 expression levels in 
CX3CR1-expressing CD8+ T cells were also significantly decreased in AD patients 
(mean fluorescence intensity, 10 ± 3) compared with normal controls (16 ± 3, 
p<0.0005); however, they were not significantly different from those in psoriasis 
patients (13 ± 4).  Similarly, AD patients had the significantly reduced frequency of 
CX3CR1+ cells in monocytes relative to normal controls (p<0.05) and psoriasis patients 
T. Echigo, et al. 
15 
(p<0.05), and CX3CR1 expression levels in CX3CR1-expressing monocytes were 
significantly lower in AD patients (11 ± 6) than those found in psoriasis patients (20 ± 5, 
p<0.005) as well as normal controls (23 ± 5, p<0.0001).  The percentage of CX3CR1+ 
cells in NK cells was also significantly lower in AD patients than in normal controls 





3CR1 expression levels in CX3CR1+ NK cells relative to normal controls (25 
± 11 vs. 36 ± 6, p<0.05) while there was no significant difference in CX3CR1 
expression levels on CX3CR1+ NK cells between AD patients and psoriasis patients (31 
± 8).  However, the frequency of CX3CR1-expressing cells in CD4+ T cells was similar 
for AD patients, normal controls, and psoriasis patients, and expression levels of 
CX3CR1 in CX3CR1+ CD4+ T cells were also similar in AD patients (4.3 ± 1.4), 
psoriasis patients (5.4 ± 1.4), and normal controls (5.6 ± 1.0).  Furthermore, the 
frequency of CX3CR1+ cells among CLA+ CD4+ T cells in AD patients (18 ± 5 %) was 
not significantly different from that in normal controls (16 ± 4 %).  In contrast, the 
frequency of CX3CR1+ cells in each leukocyte subset from psoriasis patients was 
comparable with that from normal controls.  Thus, the frequency of 
CX3CR1-expressing cells and CX3CR1 expression levels were decreased in some 
peripheral leukocyte subsets of AD. 
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DISCUSSION 
The current study showed that FKN expression was augmented in the 
cutaneous vascular endothelial cells of AD patients.  Consistent with the finding that 
up-regulated FKN expression on endothelial cells facilitates the recruitment of 
CX3CR1+ cells to the skin 17, CX3CR1-expressing leukocytes were increased in the 
affected skin of AD.  Reflecting the augmented FKN expression in the skin, serum 
sFKN levels were elevated in AD patients and associated with the disease severity and 







3CR1-expressing cells similar to other soluble chemokines 17,18,29.  Collectively, the 
results of this study suggest that, through functions of both membrane-bound and 
soluble forms, FKN regulates the CX3CR1+ leukocyte trafficking during the 
development of AD skin lesions and also suggest that the serum sFKN level is a useful 
clinical marker that reflects both the severity and activity of AD. 
Chemokines and their receptors have the capability of regulating the selective 
migration of Th1 and Th2 cells to the target tissues and of controlling the Th1 and Th2 
type responses 30-32.  Although the abnormal shift to Th2 cells in AD has been shown to 
be clear by analysis using peripheral blood 33-35, direct assessment of infiltrating cells in 
AD skin lesions is less clear-cut.  Specifically, previous studies using atopy patch tests 
with house dust mite allergens have demonstrated that a majority of T cells in the 
lesions express IFN-γ mRNA and protein, alone or in combination with IL-4 10,36,37.  
Recent studies have revealed that CCR4 plays a critical role in the migration of Th2 
cells from peripheral blood into the skin in patients with AD while Th1 cells are 
suggested to migrate from blood into the skin through CXCR3 38-40.  Since FKN is 
induced by Th1 cytokines such as IFN-γ, and CX3CR1 prefers expression on Th1 cells 
compared to Th2 cells 13,41, the enhanced FKN expression on endothelial cells may 
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mediate Th1 cells into skin lesions and thereby participate in the amplification of the 
polarized Th1 response in AD.  In this study, mRNA expression levels of FKN in the 
AD lesional skin were increased to a similar extent to those of Th2-type chemokines, 
TARC and MDC.  Furthermore, serum sFKN levels were significantly associated with 
serum levels of TARC and MDC.  These results suggest that FKN may contribute to 
the inflammation of AD in concert with TARC and MDC.  Collectively, these findings 
supports the recent hypothesis that Th1 cytokines in addition to Th2 cytokines play 







 Patients with AD exhibited elevated sFKN levels that significantly decreased 
with the improvement of skin lesions by treatment.  Since sFKN enhances the 
chemotactic activity of CX3CR1-expressing cells 12,43,44, sFKN may promote CX3CR1+ 
cell infiltration into the affected tissue.  However, recent studies have revealed that 
sFKN inhibits the adhesion of CX3CR1-expressing leukocytes to endothelial cells 
12,29,43,44.  A similar function has been reported in other adhesion molecules including 
L-selectin 45,46.  Circulating L-selectin likely serves as a biologic buffer system to 
prevent leukocyte rolling at sites of subacute inflammation 45,47.  In a similar way, the 
increase in sFKN may reflect the defence system to avoid excessive inflammatory cell 
infiltration by inhibiting the adhesion of CX3CR1+ leukocytes to endothelial cells in AD.  
Thus, although the biological significance of sFKN remains unclear, sFKN may be 
related to the inflammation associated with AD by interfering with cell to cell 
interaction.    
The percentage of CX3CR1-expressing cells and CX3CR1 expression levels 
on blood CD8+ T cells, monocytes, and NK cells were decreased in AD patients.  This 
may be caused by leukocyte activation that sheds or down-regulates CX3CR1 as 
observed in other adhesion molecules, such as intercellular adhesion molecule-1 and 
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selectins 46,48-51.  Consistent with this possibility, the percentage of CD8+ memory T 
cells expressing CX3CR1 is also decreased in patients with rheumatoid arthritis, 
suggesting that this receptor is shed or down-regulated upon lymphocyte activation 52.  
Alternatively, since expression levels of adhesion molecules generally correlate with the 
capacity to bind their receptors 53,54, leukocytes with high levels of CX3CR1 may 






3CR1 interaction, which 
results in decreased blood leukocytes with elevated CX3CR1 levels and increased 
CX3CR1+ cells in the lesional skin of AD.  Furthermore, it is possible that circulating 
sFKN directly binds to blood CX3CR1+ leukocytes and thereby down-regulates 
CX3CR1 expression.  Although the mechanisms for decreased CX3CR1 expression on 
blood leukocytes of AD patients remain unknown, it may finally contribute to 
down-regulation of the inflammation by diminishing their migration capacity into the 
inflamed skin.   
The endothelial FKN expression and frequency of infiltrating CX3CR1+ cells 
in the lesional skin were increased in psoriasis as well as AD.  By contrast, a previous 
study showed that FKN expression was enhanced in the skin from psoriasis, but not in 
AD 13.  Although the reason for this discrepancy is unclear, it may be due to the 
difference in AD populations studied since milder AD patients generally showed 
weaker FKN expression (data not shown).  Despite the increase in FKN expression 
and skin CX3CR1+ cell infiltration, serum sFKN levels and CX3CR1 expression on 
blood leukocytes in psoriasis patients were similar to normal controls, which was 
distinct from those of AD patients.  Inducible FKN cleavage from the cell surface of 
endothelial cells depends on a tumor necrosis factor-α-converting enzyme (TACE), a 
member of a family of proteins containing a disintegrin and metalloprotease domain 
(ADAMS proteins) 55,56.  TACE activity is inhibited by tissue inhibitors of 
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metalloproteinase (TIMP)-3, but not by TIMP-1, -2, and -4 57.  Since TIMP-3 
expression is augmented in psoriasis, but not in AD 58,59, the enhanced TIMP-3 
expression in psoriasis may inhibit TACE activity, perhaps resulting in reduced sFKN 
release and normal serum sFKN levels.  These normal sFKN levels may not alter 
CX3CR1 expression on circulating leukocytes from psoriasis patients.  Although the 




3CR1 expression on leukocytes 
between AD and psoriasis remain unknown, the results suggest that the contribution of 
CX3CR1-FKN interaction to the inflammation of AD is different from that of psoriasis.  
However, we cannot exclude the possibility that FKN is related to the development of 
general skin inflammation, since local FKN expression was not significantly different 
between AD and psoriasis.  Further studies will be needed to determine the relative 
importance of FKN in AD compared to other skin inflammatory diseases. 
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Fig 1.  Representative immunohistochemical expression of FKN (A) and CX3CR1 (B) 






Fig 2.  Serum levels of sFKN in patients with AD, those with psoriasis, those with 
contact dermatitis (Contact D), and normal controls (CTL).  Patients with AD were 
grouped into patients with severe AD and those with moderate AD.  Serum sFKN 
levels were determined by ELISA.  The horizontal bars represent mean values with 
statistically significant differences between groups indicated.  Note the logarithmic 
scale. 
 
Fig 3.  Representative expression of CX3CR1 on CD8+ T cells, CD4+ T cells, CD14+ 
monocytes, and CD16+ NK cells in peripheral blood from patients with AD and normal 
controls (CTL).  All samples were stained in parallel by two-color immunofluorescent 
staining of mononuclear cells and analyzed sequentially by flow cytometry with 
identical instrument settings.  Quadrants were set according to the staining of control 
mAbs.  The percentage represents the frequency of CX3CR1+ cells in each leukocyte 
subset.  Horizontal dashed lines in each histogram are provided for reference.   
 
Fig 4.  The frequency of CX3CR1+ leukocyte subpopulations from patients with AD, 
those with psoriasis, and normal controls (CTL).  The frequency of CX3CR1+ cells was 
examined on CD8+ T cells, CD4+ T cells, CD14+ monocytes, and CD16+ NK cells by 
two-color immunofluorescence staining with flow cytometric analysis, using the gates 
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shown in Fig. 3.  All samples were stained and analyzed sequentially by flow 
cytometry in parallel using identical instrument settings.  The horizontal bars represent 
mean values with statistically significant differences between groups indicated.   




